Physical Activity Associated With Improved PFS, OS in Advanced CRC
Among patients with advanced colorectal cancer, greater total physical activity improved progression-free and overall survival.
Gastrointestinal (GI) Cancers Symposium
FOLFIRI and XELIRI Are Safe, Well-tolerated in Metastatic Colorectal Cancer
Despite differences in the safety profiles and rates of adverse events, both FOLFIRI and XELIRI were safe and well-tolerated as second-line therapy.
PET Scans Inform, Improve Treatment in Esophageal Cancer
Altering chemotherapy during neoadjuvant chemoradiotherapy based on response to induction chemotherapy by PET imaging can improve pathologic complete response.
Watch-and-Wait Safe for Patients With Rectal Cancer
Omitting surgery and using a watch-and-wait approach does not compromise outcomes for selected patients with advanced rectal cancer.
Surgical Palliation for Gastric Outlet Obstruction
Among patients with malignant gastric outlet obstruction caused by gastric cancer, surgical palliation was effective for maintaining patient quality of life.
Nintedanib Improves PFS in mCRC Regardless of Prior Regorafenib Treatment
Treatment with nintedanib significantly improved progression-free survival among heavily pretreated patients with metastatic colorectal cancer (mCRC).
Tumor-Specific Differences, Genomic Alterations of Biliary Tract Cancers Identified
Gastrointestinal cancers have a diverse landscape of clinically relevant genomic alterations (CRGA) that could lead to targeted drug therapy.
eNOS Polymorphisms May Influence Prognosis in Hepatocellular Carcinoma Treated with Sorafenib
Endothelial nitric oxide synthase (eNOS) VNTR and eNOS -786 could determine outcomes in advanced hepatocellular carcinoma treated with sorafenib,
In Advanced Hepatocellular Carcinoma, Baseline AFP May Predict Response to Ramucirumab
Baseline α-fetoprotein (AFP) levels may be a predictive marker for advanced hepatocellular carcinoma receiving ramucirumab.
Similarities, Differences Between Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas
Comprehensive genomic profiling (CGP) shows promise in advanced esophageal squamous cell carcinomas (ESCC) and adenocarcinoma (EAC).
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in GI Cancers Symposium 2015
Loading... 
Loading...